Abbott

ABT

Market cap $149B

Boston Scientific and Abbott both posted solid quarterly growth, but analysts see stronger upside for Boston Scientific despite mounting operational pressures.

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Abbott (ABT) concluded the recent trading session at $85.68, signifying a -1.14% move from its prior day's close.

ABT's Diagnostics unit witnesses mixed Q1 results as Core Lab growth offsets China weakness and softer respiratory testing demand.

First-of-its-kind biowearables combine continuous glucose and ketone monitoring in a single sensor to support both daily diabetes management and help detect rising ketone levels that can lead to diabetic ketoacidosis, a serious health condition for people with diabetes Integrates with the Libre digital health ecosystem, allowing people to share glucose and ketone data with caregivers and healthcare providers Designed for compatibility with leading automated insulin delivery (AID) systems ABBOTT PARK, Ill., May 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a global healthcare leader, announced today it has secured CE Mark for the world's first dual glucose‑ketone sensing technology for people with diabetes.

Cologuard® and Cologuard Plus® reaffirmed as preferred options for noninvasive colorectal cancer (CRC) screening in updated American Cancer Society guideline Abbott to offer only CRC screening portfolio aligned to new ACS recommendations combining preferred stool-based plus additional blood-based options Recent publications support Cologuard-first strategy, demonstrating better outcomes for patients, providers, health systems, and payers ABBOTT PARK, Ill., May 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the American Cancer Society (ACS) has released updated colorectal cancer (CRC) screening guidelines that reaffirm Cologuard® and Cologuard Plus® as preferred noninvasive screening options for adults age 45 and older who are at average risk for CRC.

Data highlight how screening and diagnostics enable earlier detection, more precise treatment decisions, and improved patient outcomes from risk to remission New MRD data from the PARTNER study demonstrate enhanced sensitivity in early triple-negative breast cancer Early MCED prospective data show low anxiety and minimal psychological burden in real-world use ABBOTT PARK, Ill., May 26, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will present 11 abstracts featuring new evidence across the cancer care continuum at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago.

Barron's Oil & Blue Chip Tips for May 2026 highlight 20 stocks, with 11 deemed 'safer' based on free cash flow yields exceeding dividend yields. Top ten by yield are projected to deliver average net gains of 36.08% by May 2027, with risk/volatility 24% below the market average. Zoetis (ZTS), Danaher (DHR), and Accenture (ACN) lead in projected returns, with ZTS estimated to net 60.33% and lower-than-market volatility.

ABT's EPD unit posts 9% Q1 sales growth as biosimilars and emerging market demand support its long-term expansion plans.